Enjoy complimentary customisation on priority with our Enterprise License!
The antibody drug conjugates (ADC) market size is forecast to increase by USD 9.95 billion at a CAGR of 15.06% between 2023 and 2028. The antibody drug conjugates (ADCs) market is experiencing significant growth due to the increasing prevalence of cancer and other diseases, leading to heightened demand for effective therapeutic options. ADCs, which consist of monoclonal antibodies conjugated with cytotoxic drugs via a linker, offer targeted therapy by binding to surface antigens on tumor cells. This targeted approach reduces the side effects associated with traditional chemotherapy. However, the high development costs for ADCs pose a challenge to market growth. Multi-specific antibodies, a newer class of ADCs, are gaining attention due to their ability to target multiple antigens on tumor cells, enhancing therapeutic efficacy. The adoption and development of ADCs and multi-specific antibodies are expected to continue, driven by the need for more effective and targeted cancer treatments.
Antibody-drug conjugates (ADCs) represent a novel class of therapeutic agents that combine the specificity of monoclonal antibodies with the cytotoxic effects of small molecule drugs. This conjugation technology enables the targeted delivery of potent cytotoxic drugs to tumor cells, thereby reducing systemic toxicity and improving therapeutic efficacy. ADCs are produced by the covalent attachment of a cytotoxic payload to a carrier molecule, typically a monoclonal antibody, protein, polypeptide, lipid, polymer, or carbohydrate. The linker used to connect the payload and carrier molecule plays a crucial role in determining the stability, pharmacokinetics, and efficacy of the ADC.
Moreover, the use of ADCs in cancer therapy has gained significant attention due to their ability to selectively target surface antigens expressed on tumor cells. The immune system recognizes and binds to these antigens, allowing the ADC to be internalized into the tumor cell. Once inside, the linker is cleaved, releasing the cytotoxic drug, which inhibits the growth and proliferation of the tumor cell. Chemotherapy remains a cornerstone of cancer treatment, but its systemic administration often results in off-target effects and significant toxicity. ADCs offer a solution to this challenge by allowing for the targeted delivery of cytotoxic drugs to tumor cells, thereby reducing the overall dose required and minimizing systemic toxicity.
Additionally, antibody-drug conjugates have shown promise in the treatment of various types of cancer, including solid tumors and hematological malignancies. For instance, ADCs have been developed for the treatment of angiogenesis inhibitors, multi-specific antibodies therapy, and chemotherapy. The field of ADC research is continually evolving, with ongoing efforts to optimize the design and production of these complex molecules. The development of new linker technologies, payloads, and targeting strategies is expected to expand the therapeutic potential of ADCs and broaden their application in cancer therapy.
In conclusion, antibody-drug conjugates represent a promising advancement in the field of biopharmaceutical drugs, offering a targeted and effective approach to cancer therapy. The ability to selectively deliver cytotoxic drugs to tumor cells using ADCs holds the potential to revolutionize cancer treatment and improve patient outcomes.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The breast cancer segment is estimated to witness significant growth during the forecast period. The global market for Antibody Drug Conjugates (ADCs) is experiencing notable growth, particularly in the segment addressing breast cancer. ADCs represent a groundbreaking approach in cancer therapy, combining the targeted capabilities of monoclonal antibodies with the cytotoxic effects of chemotherapeutic agents. Breast cancer, being one of the most common types of cancer, especially among women, necessitates effective and targeted treatment options due to its high prevalence and associated mortality rates. ADCs offer a promising alternative for breast cancer treatment by specifically targeting cancer cells and delivering cytotoxic agents directly to tumor sites. ADCs employ various mechanisms, such as anti-angiogenic agents, anti-HER2 medications, and tumor antigen-specific antibodies, to combat breast cancer.
Further, these include the use of PD-L1 and Major Histocompatibility Complex (MHC) to enhance the immune response. The process of linking these agents to antibodies is called bioconjugation, which is achieved through the application of chemical linkers. Kadcyla, an established ADC for treating HER2-positive breast cancer, exemplifies the potential of this therapeutic approach. As the demand for advanced and targeted cancer treatments continues to increase, the market for ADCs is poised for continued expansion.
Get a glance at the market share of various segments Request Free Sample
The breast cancer segment was valued at USD 3.22 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 50% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
The Antibody Drug Conjugates (ADCs) market in North America is experiencing significant expansion. ADCs represent a class of innovative cancer therapies that merge cytotoxic agents, which destroy cancer cells, with monoclonal antibodies that specifically target cancer cells. The presence of numerous pharmaceutical companies, an advanced healthcare infrastructure, and favorable reimbursement policies position North America as a leading player in the global ADCs market. The US, in particular, holds the largest market share within North America due to its sophisticated healthcare facilities and high cancer prevalence. Over the coming years, the ADCs market in North America is anticipated to witness substantial growth.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The growing prevalence of cancer and other diseases is the key driver of the market. The Antibody Drug Conjugates (ADCs) market in North America is experiencing significant expansion. ADCs represent a category of innovative cancer therapies that merge cytotoxic drugs with monoclonal antibodies, which specifically bind to cancer cells. Several pharmaceutical companies, a sophisticated healthcare infrastructure, and favorable reimbursement policies position North America at the forefront of the global ADCs market. The US, in particular, holds the largest market share due to its advanced healthcare facilities and high cancer incidence.
Thus, over the coming years, the ADCs market in North America is expected to witness substantial growth, driven by the increasing demand for targeted cancer treatments and ongoing research and development efforts. These elements are crucial in ensuring the efficacy and safety of ADCs. The North American market for ADCs is poised for growth due to its strong healthcare sector, extensive research capabilities, and large patient population. The presence of key players, including Seer, Immunogen, and ADC Therapeutics, further bolsters the market's potential.
The increasing adoption and development of targeted therapies is the upcoming trend in the market. The use of Antibody Drug Conjugates (ADCs) in multi-specific antibody therapy is gaining traction in the healthcare industry. ADCs are a type of biopharmaceutical medication that employs monoclonal antibodies to target surface antigens on tumor cells and deliver cytotoxic drugs. Pharmaceutical companies and medical professionals are increasingly interested in ADCs due to their potential to effectively treat various types of cancer.
Therefore, the growing understanding of cancer's molecular mechanisms is a significant factor fueling the adoption of targeted therapies. Advancements in proteomics and genomics have enabled scientists to identify specific molecular targets that contribute to cancer cell growth and survival. Monoclonal antibodies, which are used in ADCs, bind to these targets, allowing the payload of cytotoxic drugs to be released directly into the tumor cells. This targeted approach minimizes damage to healthy cells and increases the efficacy of cancer treatment.
The high development costs for antibody drug conjugates is a key challenge affecting the market growth. Antibody-drug conjugates (ADCs) represent a significant advancement in cancer therapy, merging the precision of monoclonal antibodies with the potency of chemotherapy agents. However, the development and manufacturing of ADCs pose substantial challenges due to their intricate production processes. The creation of an effective ADC involves extensive research and development (R&D) efforts. Identifying suitable targets, designing the antibody, and attaching it to the cytotoxic agent are all critical steps that require meticulous planning and numerous iterations. These complexities contribute to the high costs associated with bringing an ADC to market. Polymer-drug conjugation is another advanced technology used in the development of ADCs.
However, this process involves attaching a polymer to the cytotoxic drug, which is then conjugated to the antibody. This approach aims to improve the stability and pharmacokinetics of the ADC, enhancing its therapeutic potential. Despite these challenges, the biopharmaceutical industry continues to invest in ADC research, driven by their potential to revolutionize cancer treatment. Antibody-drug conjugates hold promise as targeted therapies for various cancers, including those that are resistant to traditional chemotherapy.
Furthermore, ADCs show potential as angiogenesis inhibitors, making them valuable tools in the fight against cancer. In conclusion, the development of antibody-drug conjugates is a complex and costly process, but its potential benefits make it a worthwhile investment for the biopharmaceutical industry. The ability to target specific cancer cells while minimizing damage to healthy cells offers a promising approach to cancer treatment. As research and technology continue to advance, the future of ADCs looks bright.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc. - The company offers an antibody drug conjugate that consists of a cytotoxin covalently linked to a monoclonal antibody that recognizes an antigen differentially overexpressed on tumor cells.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Antibody drug conjugates (ADCs) are a type of biopharmaceutical drug that combines the targeting ability of monoclonal antibodies with the cytotoxic effects of small molecule drugs. This is achieved through conjugation, which involves attaching the cytotoxic drug to the antibody using a linker. The linker ensures the drug is released only when the ADC reaches its target, such as tumor cells with specific surface antigens. ADCs can be produced using various types of carriers, including polypeptides, proteins, lipids, polymers, and carbohydrates. Protein-drug conjugation and antibody-drug conjugation are common methods used to create ADCs. ADCs have shown promise in various therapeutic areas, including chemotherapy, immunotherapy, and anti-angiogenic agents.
In conclusion, they have been used to target specific antigens on tumor cells, such as HER2, PD-L1, MHC, and tumor antigen-specific antibodies. The use of ADCs offers several advantages over traditional chemotherapy. They allow for targeted delivery of cytotoxic drugs, reducing side effects and increasing efficacy. ADCs can also be designed to be cleavable or non-cleavable, depending on the specific application. These drugs employ various linkers and payloads, such as MMAE, DM4, and Valine Citrulline (VC), to enhance their therapeutic efficacy.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
156 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 15.06% |
|
Market growth 2024-2028 |
USD 9.95 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
14.35 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 50% |
|
Key countries |
US, Germany, UK, China, and Japan |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AbbVie Inc., Adcendo ApS, Araris Biotech AG, Astellas Pharma Inc., AstraZeneca Plc, Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., ImmunoGen Inc., Merck KGaA, Mersana Therapeutics Inc., Mythic Therapeutics, Pfizer Inc., Piramal Enterprises Ltd., PPF Group, Regeneron Pharmaceuticals Inc., Seagen Inc., Syngene International Ltd., Takeda Pharmaceutical Co. Ltd., and ADC Therapeutics SA |
|
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by Technology
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
